Merck + Co., Inc.

Ralph A Rivero

William J Greenlee

Thomas F Walsh

Daljit S Dhanoa

Kenneth J Fitch

Nancy J Kevin

Arthur A Patchett

Prasun K Chakravarty

David G Hangauer

Nathan B Mantlo

Scott William Bagley

Eric E Allen

Douglas J Pettibone

David L Williams

Theodore P Broten

Wallace T Ashton

Dooseop Kim

James R Tata

Richard B Toupence

Jay M Matthews

Daniel F Veber

Lihu Yang

Ann E Weber

Peter D Williams

Linda L Chang

Gerard R Kieczykowski

Victor J Lotti

Tomasz W Glinka

Steven M Hutchins

Peter K Siegl

Arthur A Pastchett

Gloria J Zingaro

Salah Kivlighn

Phenoxyphenylacetic acid derivatives

Phenoxyphenylacetic acids and derivatives of the general structural formula I ##STR1## have endothelin antagonist activity and are useful in treating cardiovascular disorders, such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, inflammatory diseases including Raynaud's disease and asthma.

Biphenyl compounds useful or endothelin antagonists

Substituted biphenylmethylimidazopyridines

Novel compounds of the general structural formula I: ##STR1## have endothelin antagonist activity and are therefore useful in treating cardiovascular disorders, such as hypertension, pulmonary hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, inflammatory diseases including Raynaud's disease and asthma.

Endothelin antagonists incorporating a cyclobutane

Substituted heterocycles attached through a methylene bridge to novel substituted phenyl derivatives of the Formula I are useful as angiotensin II antagonists. ##STR1## wherein the substituents are as defined in the claims.

Angiotensin II antagonists incorporating a substituted benzyl element

This invention relates to compounds represented by formula I: ##STR1## which are agonists of angiotensin II. The invention is also concerned with the use of aforementioned agonists in the treatment of states meditated by angiotensin.

Pharmaceutical treatment methods using angiotensin II receptor agonists

Heterocyclic compounds of structural formula: ##STR1## wherein A, B, C, and D are independently carbon atoms or nitrogen atoms are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.

Heterocyclic compounds bearing acidic functional groups as angiotensin

Carbamoyl and oxycarbonyl derivatives of biphenylmethylamines of structure I are angiotensin-II antagonists with balanced AT.sub.1 and AT.sub.2 activity useful in the treatment of hypertension and related disorders and ocular hypertension. ##STR1## where X is --O-- or --N(R.sup.7)--.

Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines

Substituted heterocycles attached through a methylene bridge to novel substituted phenyl derivatives of the Formula I are useful as angiotensin II antagonists. ##STR1##

Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists

Substituted heterocycles attached through a methylene bridge to novel substituted phenyl thiophene or phenyl furan derivative of the Formula I are useful as angiotensin II antagonists. ##STR1##

Angiotensin II antagonists incorporating a substituted thiophene or furan

Angiotensin II antagonists incorporating a substituted pyridoimidazolyl

Substituted imidazo[4,5-b]pyridines of structural formula: ##STR1## are angiotensin II antagonists useful in the treatment of hypertension and congestive heart failure.

6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists

Substituted imidazoles attached through a methylene bridge to novel substituted phenyl thiophene or phenyl furan derivative of the Formula I are useful as angiotensin II antagonists. ##STR1##

Compounds of the formula ##STR1## are disclosed. These compounds inhibit the angiotensinogen-cleaving action of the natural proteolytic enzyme, renin, are useful in treating, preventing or managing renin-associated hypertension, hyperaldosteronism, congestive heart failure, and glaucoma.

Cyclic renin inhibitors containing 2-substituted

Growing community of inventors

Tinton Falls, NJ, United States of America

Ralph A Rivero